OmniAb (NASDAQ:OABIW – Get Free Report) will likely be releasing its results before the market opens on Wednesday, March 4th. Analysts expect OmniAb to post earnings of ($0.0880) per share and revenue of $9.0030 million for the quarter.
OmniAb Trading Down 0.3%
Shares of NASDAQ OABIW opened at $0.09 on Monday. The business’s 50 day moving average is $0.10 and its 200-day moving average is $0.14. OmniAb has a 1-year low of $0.08 and a 1-year high of $0.63.
About OmniAb
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
Recommended Stories
- Five stocks we like better than OmniAb
- Silver Crossed $100: Is the $500 surge next? (Join us March 4)
- America’s 1776 happening again
- Unlocked: Elon Musk’s Next Big IPO
- Silver paying 20% dividend. Plus 68% share gains
- REVEALED: Something Big Happening Behind White House Doors
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
